Evidence mapPaperPMID 38719806Full record

ArticleCell death discovery2024

Unique lipid composition maintained by extracellular blockade leads to prooncogenicity.

Kai Kudo, Ryo Yanagiya, Masanori Hasegawa, Joaquim Carreras, Yoshimi Miki, Shunya Nakayama, Etsuko Nagashima, Yuji Miyatake, Kan Torii, Kiyoshi Ando and 4 more

Abstract read
In one paragraph

Article in Cell death discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kai Kudo *Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Ryo Yanagiya *Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-2092-8194
Masanori HasegawaDepartment of Urology, Tokai University School of Medicine, Isehara, Kanagawa, Japan. hasem@tsc.u-tokai.ac.jp.ORCID http://orcid.org/0000-0002-4354-6105
Joaquim CarrerasDepartment of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-6129-8299
Yoshimi MikiLaboratory of Microenvironmental Metabolic Health Sciences, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8587-0333
Shunya NakayamaDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Etsuko NagashimaDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Yuji MiyatakeDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Kan ToriiDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Kiyoshi AndoDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Naoya NakamuraDepartment of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Akira MiyajimaDepartment of Urology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Makoto MurakamiLaboratory of Microenvironmental Metabolic Health Sciences, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ai KotaniDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan. aikotani@k-lab.jp.ORCID http://orcid.org/0000-0002-0976-8687

Funding

MEXT | Japan Science and Technology Agency (JST) JPMJCR19H5MEXT | Japan Society for the Promotion of Science (JSPS) 2021-B04MEXT | Japan Society for the Promotion of Science (JSPS) JP19K07042MEXT | Japan Society for the Promotion of Science (JSPS) JP20H03716MEXT | Japan Society for the Promotion of Science (JSPS) JP20H05691MEXT | Japan Society for the Promotion of Science (JSPS) JP22K06577MEXT | Japan Society for the Promotion of Science (JSPS) JP22K20838
6 · The paper itself

Abstract

Lipid-mediated inflammation is involved in the development and malignancy of cancer. We previously demonstrated the existence of a novel oncogenic mechanism utilizing membrane lipids of extracellular vesicles in Epstein-Barr virus (EBV)-positive lymphomas and found that the lipid composition of lymphoma cells is skewed toward ω-3 fatty acids, which are anti-inflammatory lipids, suggesting an alteration in systemic lipid composition. The results showed that arachidonic acid (AA), an inflammatory lipid, was significantly reduced in the infected cells but detected at high levels in the sera of EBV-positive patients lead to the finding of the blockade of extracellular AA influx by downregulating FATP2, a long-chain fatty acid transporter that mainly transports AA in EBV-infected lymphoma cells. Low AA levels in tumor cells induced by downregulation of FATP2 expression confer resistance to ferroptosis and support tumor growth. TCGA data analysis and xenograft models have demonstrated that the axis plays a critical role in several types of cancers, especially poor prognostic cancers, such as glioblastoma and melanoma. Overall, our in vitro, in vivo, in silico, and clinical data suggest that several cancers exert oncogenic activity by maintaining their special lipid composition via extracellular blockade.

Identifiers

PMID38719806
PMCPMC11079073

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.